CHNA

Loncar China BioPharma ETF
*Unless otherwise stated, data provided by FactSet.

CHNA Fund Description

CHNA tracks a tier-weighted index of companies directly involved in the growth of China’s pharmaceutical and biotech industry.

CHNA Factset Analytics Insight

CHNA targets China’s pharmaceutical and biotech (biopharma) sector. The fund includes pharmaceutical companies, biotech companies, drug manufacturers, diagnostics companies, wholesalers or distributors of biopharma products, and biopharma service providers. It is worth noting that manufacturers of pharmaceutical ingredients are excluded, as the fund focuses on innovation in the sector. CHNA uses a tiered weighting system. Starting from equal weight, all qualified constituents are assigned a weight adjustment based on market cap. Large cap stocks get a 140% adjustment, midcaps 100%, and small-caps 70%. The index is reconstituted on every second Monday of each February and August.

CHNA MSCI ESG Analytics Insight

Loncar China BioPharma ETF has an MSCI ESG Fund Rating of undefined based on a score of 5.10 out of 10. The MSCI ESG Fund Rating measures the resiliency of portfolios to long-term risks and opportunities arising from environmental, social, and governance factors. ESG Fund Ratings range from best (AAA) to worst (CCC). Highly rated funds consist of companies that tend to show strong and/or improving management of financially relevant environmental, social and governance issues. These companies may be more resilient to disruptions arising from ESG events.

The fund’s Peer Rank reflects the ranking of a fund’s MSCI ESG Fund Quality Score against the scores of other funds within the same peer group, as defined by the Thomson Reuters Lipper Global Classification. Loncar China BioPharma ETF ranks in the 28th percentile within its peer group and in the 86th percentile within the global universe of all funds covered by MSCI ESG Fund Ratings.

CHNA MSCI FaCS and Factor Box

MSCI FaCS is a standard method for evaluating and reporting the Factor characteristics of equity portfolios including ETFs. The Factor Box includes 6 Factors that MSCI has identified that historically provided a return premium. On the vertical axis, the Factor Groups, are displayed and the horizontal axis displays the Factor exposure, overweight, underweight or neutral.

PERFORMANCE [as of 10/14/21] 1 MONTH 3 MONTHS YTD 1 YEAR 3 YEARS 5 YEARS 10 YEARS
CHNA -10.09% -21.94% 8.96% 12.43% 21.53% -- --
CHNA (NAV) -10.56% -22.63% 7.50% 12.94% 21.13% -- --
Loncar China BioPharma Index -10.52% -22.52% 8.08% 13.73% 22.19% -- --
N/A -- -- -- -- -- -- --
All returns over 1 year are annualized. All returns are total returns unless otherwise stated.

CHNA Summary Data

Loncar
08/14/18
Open-Ended Fund
0.79%
$14.16M
$84.28K
0.80%
CHB

CHNA Portfolio Data

$8.19B
-28.10
3.36
0.44%
N/A
68

CHNA Index Data

Loncar China BioPharma Index
Tiered
Market Cap
N/A

CHNA Portfolio Management

0.79%
-1.23%
-0.76%
-1.56%

CHNA Tax Exposures

20.00% / 39.60%
--
Qualified dividends
No

CHNA Fund Structure

Open-Ended Fund
No
No
-- / --
N/A
N/A
High
Daily

CHNA Factset Analytics Block Liquidity

As of 10/15/21
5
4
3
2
1

This measurement shows how easy it is to trade a $1 million USD block of CHNA. CHNA is rated a 1 out of 5.

CHNA Tradability

2,215
$84.28K
1,675
$62.37K
0.80%
$0.31
-0.14%
2.66% / -2.81%
None
12.00%
25,000
0.07
0.08%
0.73%
0
$35.42
1

CHNA Top 10 Holdings[View All]

2.60%
2.53%
2.50%
2.34%
2.26%
2.15%
2.10%
2.09%
2.08%
23.16%

CHNA Countries


CHNA
Segment Benchmark
90.50%
--
9.50%
--

CHNA Regions


CHNA
Segment Benchmark
100.00%
--

CHNA Economic Development


CHNA
Segment Benchmark
90.50%
--
9.50%
--

CHNA Performance Statistics

--
--
--
--
0.00%
N/A

CHNA MSCI ESG Ratings

--
5.10 / 10
86.18
28.11
1.51%
--
78.65

CHNA Benchmark Comparison Holdings

68
--
--
0.00%

CHNA Benchmark Comparison Summary


CHNA
Segment Benchmark
68
--
$8.19B
--
-28.10
--
3.36
--
0.68%
--
Low
High

CHNA Benchmark Comparison Market Cap Size


CHNA
Segment Benchmark
20.04%
--
35.22%
--
38.62%
--
6.12%
--